News Gilead rescinds orphan status request for COVID-19 drug Gilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over its pricing should it get to market.
News Shire plans filing for HAE drug after phase 3 success Lanadelumab could revolutionise treatment of swelling disease.
News EUSA Pharma approval fills gap in neuroblastoma market Company can move in after United Therapeutics withdrew its product Unituxin
News EU regulators back two more orphan drugs, question of pricin... Two orphan medicines are heading towards the European market, after regulators recommended rare disease drugs from Biogen and BioMarin.
News Novartis and Allergan to combine drugs in NASH Swiss pharma also aims for new CAR-T therapy indication.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.